Treatment of the cbl B form of methylmalonic acidaemia with adenosylcobalamin

M. L. Batshaw, G. H. Thomas, S. R. Cohen, Reuben Matalon, M. J. Mahoney

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A 30-month-old girl was found to have the cbl B mutant form of methylmalonic aciduria by complementation analysis of fibroblasts. She was unresponsive to hydroxycobalamin and was treated with intramuscular adenosylcobalamin (AdoCbl), the deficient coenzyme, at a dose of 1 mg/24 h during a period of clinical stability. Serum cobalamin increased from 770 to 54 200 pg/ml. Mean urinary methylmalonic acid excretion was 409 mg/24 h prior to therapy. There was a transient fall in methylmalonic acid excretion during the first 5 days of therapy (range 167-245 mg/24 h) followed by a rise in excretion toward pretreatment levels (range 317-485 mg/24 h) during the second week of AdoCbl treatment. There was no change in plasma ammonia, glycine or serum bicarbonate level. We interpret the failure of this child to have a sustained and clinically significant response to AdoCbl as indicating that AdoCbl did not reach or enter the mitochondria intact, or in some other way was unavailable as a coenzyme for the methylmalonyl CoA mutase apoenzyme.

Original languageEnglish (US)
Pages (from-to)65-68
Number of pages4
JournalJournal of Inherited Metabolic Disease
Volume7
Issue number2
DOIs
StatePublished - Jun 1984
Externally publishedYes

Fingerprint

Methylmalonic Acid
Coenzymes
Methylmalonyl-CoA Mutase
Hydroxocobalamin
Apoenzymes
Therapeutics
Vitamin B 12
Bicarbonates
Serum
Ammonia
Glycine
Mitochondria
Fibroblasts
cobamamide
Methylmalonic acidemia

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Endocrinology

Cite this

Treatment of the cbl B form of methylmalonic acidaemia with adenosylcobalamin. / Batshaw, M. L.; Thomas, G. H.; Cohen, S. R.; Matalon, Reuben; Mahoney, M. J.

In: Journal of Inherited Metabolic Disease, Vol. 7, No. 2, 06.1984, p. 65-68.

Research output: Contribution to journalArticle

Batshaw, M. L. ; Thomas, G. H. ; Cohen, S. R. ; Matalon, Reuben ; Mahoney, M. J. / Treatment of the cbl B form of methylmalonic acidaemia with adenosylcobalamin. In: Journal of Inherited Metabolic Disease. 1984 ; Vol. 7, No. 2. pp. 65-68.
@article{f5c2845784dc40359058c96d993d4ecf,
title = "Treatment of the cbl B form of methylmalonic acidaemia with adenosylcobalamin",
abstract = "A 30-month-old girl was found to have the cbl B mutant form of methylmalonic aciduria by complementation analysis of fibroblasts. She was unresponsive to hydroxycobalamin and was treated with intramuscular adenosylcobalamin (AdoCbl), the deficient coenzyme, at a dose of 1 mg/24 h during a period of clinical stability. Serum cobalamin increased from 770 to 54 200 pg/ml. Mean urinary methylmalonic acid excretion was 409 mg/24 h prior to therapy. There was a transient fall in methylmalonic acid excretion during the first 5 days of therapy (range 167-245 mg/24 h) followed by a rise in excretion toward pretreatment levels (range 317-485 mg/24 h) during the second week of AdoCbl treatment. There was no change in plasma ammonia, glycine or serum bicarbonate level. We interpret the failure of this child to have a sustained and clinically significant response to AdoCbl as indicating that AdoCbl did not reach or enter the mitochondria intact, or in some other way was unavailable as a coenzyme for the methylmalonyl CoA mutase apoenzyme.",
author = "Batshaw, {M. L.} and Thomas, {G. H.} and Cohen, {S. R.} and Reuben Matalon and Mahoney, {M. J.}",
year = "1984",
month = "6",
doi = "10.1007/BF01805805",
language = "English (US)",
volume = "7",
pages = "65--68",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Treatment of the cbl B form of methylmalonic acidaemia with adenosylcobalamin

AU - Batshaw, M. L.

AU - Thomas, G. H.

AU - Cohen, S. R.

AU - Matalon, Reuben

AU - Mahoney, M. J.

PY - 1984/6

Y1 - 1984/6

N2 - A 30-month-old girl was found to have the cbl B mutant form of methylmalonic aciduria by complementation analysis of fibroblasts. She was unresponsive to hydroxycobalamin and was treated with intramuscular adenosylcobalamin (AdoCbl), the deficient coenzyme, at a dose of 1 mg/24 h during a period of clinical stability. Serum cobalamin increased from 770 to 54 200 pg/ml. Mean urinary methylmalonic acid excretion was 409 mg/24 h prior to therapy. There was a transient fall in methylmalonic acid excretion during the first 5 days of therapy (range 167-245 mg/24 h) followed by a rise in excretion toward pretreatment levels (range 317-485 mg/24 h) during the second week of AdoCbl treatment. There was no change in plasma ammonia, glycine or serum bicarbonate level. We interpret the failure of this child to have a sustained and clinically significant response to AdoCbl as indicating that AdoCbl did not reach or enter the mitochondria intact, or in some other way was unavailable as a coenzyme for the methylmalonyl CoA mutase apoenzyme.

AB - A 30-month-old girl was found to have the cbl B mutant form of methylmalonic aciduria by complementation analysis of fibroblasts. She was unresponsive to hydroxycobalamin and was treated with intramuscular adenosylcobalamin (AdoCbl), the deficient coenzyme, at a dose of 1 mg/24 h during a period of clinical stability. Serum cobalamin increased from 770 to 54 200 pg/ml. Mean urinary methylmalonic acid excretion was 409 mg/24 h prior to therapy. There was a transient fall in methylmalonic acid excretion during the first 5 days of therapy (range 167-245 mg/24 h) followed by a rise in excretion toward pretreatment levels (range 317-485 mg/24 h) during the second week of AdoCbl treatment. There was no change in plasma ammonia, glycine or serum bicarbonate level. We interpret the failure of this child to have a sustained and clinically significant response to AdoCbl as indicating that AdoCbl did not reach or enter the mitochondria intact, or in some other way was unavailable as a coenzyme for the methylmalonyl CoA mutase apoenzyme.

UR - http://www.scopus.com/inward/record.url?scp=0021184176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021184176&partnerID=8YFLogxK

U2 - 10.1007/BF01805805

DO - 10.1007/BF01805805

M3 - Article

C2 - 6434828

AN - SCOPUS:0021184176

VL - 7

SP - 65

EP - 68

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 2

ER -